Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
journal contributionposted on 31.08.2021, 16:44 by Frank MoriartyFrank Moriarty, James LarkinJames Larkin, Tom FaheyTom Fahey
Background: The pharmaceutical industry makes large numbers of payments to healthcare organisations (HCOs) and healthcare professionals (HCPs). Ireland has a large pharmaceutical industry presence and national debate on legislating for greater industry payment transparency. This study characterises payments in Ireland to HCPs and HCOs during 2015-2019, and the content, consistency and methodology of the data source.
Methods: An observational study of TransfersOfValue.ie, the disclosure website for the Irish Pharmaceutical Health Association pharmaceutical companies. We conducted a quantitative analysis, summarising payments to HCOs, HCPs and for research and development (R&D). We quantified disclosure rates of names for HCP and HCO payment recipients. We also conducted a content analysis of the methodology notes and website content.
Results: Payments totalling €163 million were reported by 47 companies during 2015-2019, €84.6 million for R&D, with non-R&D payments of €45.1 million to HCOs and €33.6 million to HCPs. HCOs were named for 91.2% of payments, and HCPs for 55.1-62.8% across study years. For 2019, ten companies disclosed >€1 million in payments, and three disclosed >€1 million in HCO and HCP payments. Content analysis of 132 data reports and 46 methodology notes indicated substantial variation in methodologies for reporting between companies.
Conclusions: There are substantial payments in Ireland, often the recipient is undisclosed, and companies differ in their reporting. A mandatory disclosure system could enhance transparency.
HRB Centre for Primary Care Research (HRC/2014/1)
CommentsThe original article is available at https://www.sciencedirect.com/
Published CitationMoriarty F, Larkin J, Fahey T. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study. Health Policy. 2021:S0168-8510(21)00201-3.
Publication Date3 August 2021
- School of Pharmacy and Biomolecular Sciences
- General Practice
- Population Health and Health Services
- Accepted Version (Postprint)